Aligos Therapeutics Presents Positive Data at The Liver Meeting 2025

Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodium

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations, including one oral presentation, at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting 2025, being held November 7 – 11, 2025 in Washington, D.C.

The oral and poster presentations highlighted the best-in-class potential of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection.

Pevifoscorvir Sodium Post Treatment Data

Newly presented data highlight outcomes for treatment-naïve or currently not treated HBeAg+ and HBeAg- subjects who completed 96 weeks of 300 mg pevifoscorvir sodium monotherapy, followed by 8 weeks of nucleos(t)ide analog (NA) monotherapy. Among HBeAg+ subjects, 8 of 10 subjects transitioned to NA monotherapy; of these, 6 (75%) maintained HBV DNA levels below the lower limit of quantification (LLOQ; 10 IU/mL, target detected [TD] or target not detected [TND]) throughout the NA only 8-week follow-up period. In the HBeAg- subjects, 8 of 9 subjects switched to NA monotherapy, and all 8 (100%) subjects maintained HBV DNA < LLOQ (10 IU/mL, TD or TND) throughout the NA only 8-week follow-up period. Reductions in HBV antigen and HBV RNA were also maintained during the NA-only 8-week follow-up period. Notably, these viral biomarkers, such as HBV antigens and HBV RNA, are typically unaffected by NA therapy, suggesting that pevifoscorvir sodium may reduce the cccDNA pool through engagement of its secondary mechanism of action.

Additionally, preclinical in vitro data demonstrated that ALG-001075, the active parent moiety of pevifoscorvir sodium, can prevent cccDNA formation and HBV DNA integration. This finding is further supported by cell-based studies presented at the meeting, which showed prevention of cccDNA establishment and HBV DNA integration following treatment with ALG-001075 (Poster #1251).

96 Week Pevifoscorvir Sodium Monotherapy Data

Additionally, the complete 96-week data from the Phase 1 monotherapy (NCT04536337) cohorts were presented showing the continued potential of pevifoscorvir sodium to become first-line therapy for chronic suppression.